Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 107
Filter
2.
Int J Lab Hematol ; 36(2): 184-96, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24118926

ABSTRACT

INTRODUCTION: The extension of quantitative flow cytometric studies to the erythroid lineage in patients with suspected myelodysplastic syndrome has prompted a reassessment of cell surface antigen expression during normal erythropoiesis. Erythropoiesis in normal and pathologic bone marrows was studied to determine the expected antigenic relationships of maturing erythroid cells. METHODS: A total of 200 bone marrow specimens were evaluated by multidimensional flow cytometry (MDF). Samples were prepared using either NH4 Cl lysis or Ficoll density gradient separation. RESULTS: Normal erythroid development is described as a two-step process observable with the intensity relationships between CD235a, CD71, CD45, CD105, CD34, CD117, and CD36. The variability of these intensities (CV) was determined. A comparison of processing techniques determined lysis is the optimal analytic technique for the analysis of early-stage erythroid cells. Nucleic acid staining with DRAQ5 revealed that Ficoll allows for the analysis of reticulocytes and mature erythrocytes otherwise eliminated by lysis. CONCLUSION: These data demonstrate while lysis alters the light scatter characteristics of erythroid precursors, it did not alter quantitative antigen expression or nucleic acid content. The expected variability in antigen intensities is defined. These studies provide a basis for a comparison of erythroid development between normal individuals and those with erythroid dysplasia associated with myelodysplastic syndromes.


Subject(s)
Erythropoiesis/physiology , Flow Cytometry/methods , Antigens, CD/metabolism , Bone Marrow , Bone Marrow Cells/cytology , Bone Marrow Cells/metabolism , Cell Cycle , Cell Differentiation , Humans , Immunophenotyping/methods , Specimen Handling/methods , Specimen Handling/standards
3.
Tissue Antigens ; 79(5): 359-66, 2012 May.
Article in English | MEDLINE | ID: mdl-22489945

ABSTRACT

Somatic mutations and genomic alterations are frequent events in the clonal evolution of hematologic malignancies. Recent studies have reported copy neutral loss of heterozygosity (LOH) for the mismatched human leukocyte antigen (HLA) haplotype in patients relapsed after haploidentical hematopoietic cell transplantation (HCT) for a hematologic malignancy. Herein, we report 15 cases of somatic mutations in the HLA genes of patients with a variety of hematologic diseases, including acute myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, and non-Hodgkin's lymphoma, encountered at our institute over the past decade. While two of the cases were identified in patient relapse specimens collected post-HCT, 13 cases were found in peripheral blood specimens submitted for HLA typing prior to transplantation. Ten patients exhibited acquired LOH for all or part of one HLA haplotype. Five other cases involved somatic mutations in the nucleotide sequences of common HLA-A or HLA-B alleles. Since they are not systematically evaluated prior to HCT, acquired mutations in HLA genes are likely under reported. Beyond the implications for accurate HLA typing and donor selection, alternations that result in the loss of HLA expression may allow escape from immune surveillance and adversely impact transplant outcome.


Subject(s)
HLA-A Antigens/genetics , HLA-B Antigens/genetics , Hematologic Neoplasms/genetics , Leukemia/genetics , Lymphoma, Non-Hodgkin/genetics , Adult , Child , Haplotypes , Hematopoietic Stem Cell Transplantation , Histocompatibility Testing , Humans , Loss of Heterozygosity , Middle Aged , Mutation , Polymorphism, Genetic
4.
Leukemia ; 26(7): 1730-41, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22307178

ABSTRACT

Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.


Subject(s)
Biomarkers, Tumor/metabolism , Flow Cytometry/standards , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/metabolism , Practice Guidelines as Topic/standards , Bone Marrow/metabolism , Bone Marrow/pathology , Flow Cytometry/methods , Humans , Immunophenotyping , International Agencies , Myelodysplastic Syndromes/immunology , Prognosis , Reference Standards , Societies, Scientific
5.
Bone Marrow Transplant ; 40(7): 633-42, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17660844

ABSTRACT

This study was designed to determine the safety of a nonmyeloablative regimen in patients with primary immunodeficiency disorders (PID) who had infections, organ dysfunction or other risk factors that precluded conventional hematopoietic cell (HC) transplant. Fourteen patients received HLA-matched related (n=6) or unrelated (n=8) HC grafts from marrow (n=8), peripheral blood mononuclear cells (n=5) or umbilical cord blood (n=1), either without conditioning (n=1), or after 200 cGy total body irradiation alone (n=3) or with 90 mg/m2 fludarabine (n=10). All patients were given postgrafting immunosuppression with mycophenolate mofetil and cyclosporine. Mixed (n=5) or full (n=8) donor chimerism was established in 13 patients, and one patient rejected the graft. Eight patients developed acute grade III (n=1) and/or extensive chronic GVHD (n=8). With a median follow-up of 4.9 (range, 0.7-8.1) years, the 3-year overall survival, event-free survival and transplant-related mortality were 62, 62 and 23%, respectively. Correction of immune dysfunction was documented in 8 of 10 patients with stable donor engraftment. These preliminary results indicated that this approach was associated with stable donor engraftment and a low incidence of early mortality and, thus, can be considered for certain high-risk patients with PID. However, there was a risk of GVHD, which is an undesirable outcome for this group of patients.


Subject(s)
HLA Antigens/immunology , Hematopoietic Stem Cell Transplantation/methods , Immunologic Deficiency Syndromes/therapy , Adolescent , Adult , Cause of Death , Child , Child, Preschool , Follow-Up Studies , Graft vs Host Disease/epidemiology , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/mortality , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Infant , Patient Selection , Pilot Projects , Survival Analysis , Survivors , Transplantation Chimera , Transplantation Conditioning , Whole-Body Irradiation
7.
Leukemia ; 16(9): 1627-36, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12200674

ABSTRACT

We analyzed the safety and efficacy of Mylotarg (gemtuzumab ozogamicin, an antibody-targeted chemotherapy consisting of a humanized anti-CD33 antibody linked to calicheamicin, a potent antitumor antibiotic) in the treatment of 101 patients > or =60 years of age with acute myeloid leukemia (AML) in untreated first relapse in three open-label trials. Mylotarg is administered as a 2-h intravenous infusion at 9 mg/m(2) for two doses with 14 days between doses. The overall remission rate was 28%, with complete remission (CR) in 13% of patients and complete remission with incomplete platelet recovery (CRp) in 15%. Median survival was 5.4 months for all patients and 14.5 months and 11.8 months for patients achieving CR and CRp, respectively. CD33 antigen is present on normal hematopoietic progenitor cells; thus, an expected high incidence of grade 3 or 4 neutropenia (99%) and thrombocytopenia (99%) was observed. The incidences of grade 3 or 4 elevations of bilirubin and hepatic transaminases were 24% and 15%, respectively. There was a low incidence of grade 3 or 4 mucositis (4%) and infections (27%) and no treatment-related cardiotoxicity, cerebellar toxicity, or alopecia. Mylotarg is an effective treatment for older patients with CD33-positive AML in first relapse and has acceptable toxicity.


Subject(s)
Aminoglycosides , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Immunotoxins/therapeutic use , Leukemia, Myeloid/drug therapy , Neoplasm Recurrence, Local/drug therapy , Acute Disease , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Disease-Free Survival , Female , Gemtuzumab , Humans , Leukemia, Myeloid/diagnosis , Leukemia, Myeloid/mortality , Leukemia, Myeloid/pathology , Male , Middle Aged , Monitoring, Physiologic , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Prognosis , Sialic Acid Binding Ig-like Lectin 3 , Survival Rate
8.
Blood ; 98(10): 3058-65, 2001 Nov 15.
Article in English | MEDLINE | ID: mdl-11698291

ABSTRACT

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor (TNF) family, binds to several cell-surface receptors with distinct functions (agonistic receptors 1 and 2 [TRAIL-R1, TRAIL-R2]; decoy receptors 3 and 4 [TRAIL-R3, TRAIL-R4]). Expression and function was characterized in patients with myelodysplastic syndromes (MDSs). While normal marrow showed negligible expression of TRAIL and receptors (except TRAIL-R3), TRAIL and all receptors were constitutively expressed in MDS marrow. Following TRAIL exposure, MDS marrow showed significant increases in apoptosis, whereas normal marrow, except for a subset of CD34+ precursors, did not (P =.012). Marrow from 21 patients with MDS was then propagated in long-term cultures in the presence or absence of TRAIL. While in advanced MDS (refractory anemia with excess blasts in transformation [RAEB-T] and tAML [MDS transformed into AML]), colony numbers decreased in the presence of TRAIL (63.0% +/- 10.4% of untreated group [100%]), numbers increased in patients with RA or RAEB (160.2% +/- 90.5% of untreated group). TRAIL eliminated preferentially clonally abnormal cells as identified by chromosomal markers. Thus, TRAIL and receptor expression differed significantly between normal and MDS marrow, and TRAIL modulated in vitro hemopoiesis in MDS dependent upon disease stage but not, to a detectable extent, in normal marrow.


Subject(s)
Hematopoiesis , Intracellular Signaling Peptides and Proteins , Membrane Glycoproteins/biosynthesis , Myelodysplastic Syndromes/metabolism , Receptors, Tumor Necrosis Factor/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis , Aneuploidy , Apoptosis , Apoptosis Regulatory Proteins , Blotting, Western , Bone Marrow Cells/metabolism , CASP8 and FADD-Like Apoptosis Regulating Protein , Carrier Proteins/biosynthesis , Carrier Proteins/genetics , Cells, Cultured/metabolism , Chromosome Aberrations , Colony-Forming Units Assay , GPI-Linked Proteins , Gene Expression Regulation , Hematopoietic Cell Growth Factors/pharmacology , Humans , In Situ Hybridization, Fluorescence , Leucine Zippers , Membrane Glycoproteins/genetics , Membrane Glycoproteins/pharmacology , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/pathology , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , RNA, Messenger/biosynthesis , Receptors, TNF-Related Apoptosis-Inducing Ligand , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor, Member 10c , Recombinant Fusion Proteins/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , TNF-Related Apoptosis-Inducing Ligand , Tumor Necrosis Factor Decoy Receptors , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/pharmacology
9.
J Clin Oncol ; 19(13): 3244-54, 2001 Jul 01.
Article in English | MEDLINE | ID: mdl-11432892

ABSTRACT

PURPOSE: Three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, Philadelphia, PA), an antibody-targeted chemotherapy agent, in patients with CD33-positive acute myeloid leukemia (AML) in untreated first relapse. PATIENTS AND METHODS: The study population comprised 142 patients with AML in first relapse with no history of an antecedent hematologic disorder and a median age of 61 years. All patients received Mylotarg as a 2-hour intravenous infusion, at a dose of 9 mg/m(2), at 2-week intervals for two doses. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS: Thirty percent of patients treated with Mylotarg obtained remission as characterized by 5% or less blasts in the marrow, recovery of neutrophils to at least 1,500/microL, and RBC and platelet transfusion independence. Although patients treated with Mylotarg had relatively high incidences of myelosuppression, grade 3 or 4 hyperbilirubinemia (23%), and elevated hepatic transaminase levels (17%), the incidences of grade 3 or 4 mucositis (4%) and infections (28%) were relatively low. There was a low incidence of severe nausea and vomiting (11%) and no treatment-related cardiotoxicity, cerebellar toxicity, or alopecia. Many patients received Mylotarg on an outpatient basis (38% and 41% of patients for the first and second doses, respectively). Among the 142 patients, the median total duration of hospitalization was 24 days; 16% of patients required 7 days of hospitalization or less. CONCLUSION: Administration of the antibody-targeted chemotherapy agent Mylotarg to patients with CD33-positive AML in first relapse induces complete remissions with what appears to be a favorable safety profile.


Subject(s)
Aminoglycosides , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Immunotoxins/therapeutic use , Leukemia, Myeloid/drug therapy , Acute Disease , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/pharmacology , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Disease-Free Survival , Europe/epidemiology , Female , Gemtuzumab , Humans , Immunotoxins/adverse effects , Immunotoxins/pharmacology , Leukemia, Myeloid/diagnosis , Leukemia, Myeloid/mortality , Male , Middle Aged , Multivariate Analysis , North America/epidemiology , Prognosis , Recurrence , Sialic Acid Binding Ig-like Lectin 3 , Survival Rate
10.
Curr Protoc Cytom ; Chapter 10: Unit 10.4, 2001 May.
Article in English | MEDLINE | ID: mdl-18770678

ABSTRACT

The complexity of cell populations requires careful selection of reagents to detect cells of interest and distinguish them from other types. Additional reagents are frequently used to provide independent criteria for cell identification. Two or three monoclonal antibodies in combination with forward and right-angle light scatter generate a data set that is difficult to visualize because the data must be represented in four- or five-dimensional space. The separation between cell populations provided by the multiple characteristics is best visualized by multidimensional analysis using all parameters simultaneously to identify populations within the resulting hyperspace. Groups of cells are distinguished based on a combination of characteristics not apparent in any usual two-dimensional representation of the data.


Subject(s)
Database Management Systems/standards , Flow Cytometry/instrumentation , Flow Cytometry/methods , Immunophenotyping/methods , Information Systems/standards , Animals , Computational Biology/methods , Computers , Data Interpretation, Statistical , Humans , Immunophenotyping/instrumentation , Light , Programming Languages , Scattering, Radiation , Software
11.
Blood ; 96(6): 2310-3, 2000 Sep 15.
Article in English | MEDLINE | ID: mdl-10979983

ABSTRACT

Children with neurofibromatosis type 1 (NF1) carry germline mutations in one allele of the NF1 gene and are predisposed to myeloid malignancies, particularly juvenile myelomonocytic leukemia (JMML). Disruption of the remaining NF1 allele can be found in malignant cells. Flow cytometric cell sorting techniques to isolate the malignant cell populations and molecular genetic methods to assay for somatic loss of the normal NF1 allele were used to study an unusual child with NF1 and JMML who subsequently had T-cell lymphoma. The data show that malignant JMML and lymphoma cells share a common loss of genetic material involving the normal NF1 gene and approximately 50 Mb of flanking sequence, suggesting that the abnormal T-lymphoid and myeloid populations were derived from a common precursor cell. These data support the hypothesis that JMML can arise in a pluripotent hematopoietic cell.


Subject(s)
Leukemia, Myelomonocytic, Acute/etiology , Leukemia, Myelomonocytic, Acute/genetics , Lymphoma, T-Cell/etiology , Lymphoma, T-Cell/genetics , Neoplastic Stem Cells/pathology , Nerve Tissue Proteins/genetics , Cell Differentiation , Child, Preschool , Dosage Compensation, Genetic , Humans , Leukemia, Myelomonocytic, Acute/pathology , Lymphoma, T-Cell/pathology , Male , Neoplasms, Second Primary , Neurofibromin 1
12.
Leuk Lymphoma ; 37(3-4): 405-14, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10752992

ABSTRACT

The mechanism that leads to hemopoietic failure in patients with myelodysplastic syndrome (MDS) is not well understood. There is evidence, however, that regulatory molecules such as tumor necrosis factor (TNF)-alpha, Fas (CD95), and Fas-ligand, which negatively affect hemopoiesis by way of apoptosis are upregulated. Here we analyzed marrow samples from 80 patients with MDS in regard to TNF-alpha and Fas-ligand levels and a possible correlation with various disease parameters and risk factors. TNF-alpha levels were elevated in comparison to samples from normal marrow donors, however, no significant correlation with FAB subtype, cytogenetic risk group or score by the International Prognostic Scoring System (IPSS) was observed. However, there was an inverse correlation between the cytogenetic risk category (low, intermediate, high) and levels of soluble Fas-ligand. The major source of TNF-alpha were mononuclear (non-stromal) cells which appeared to produce TNF-alpha at maximum levels. Limiting dilution analysis of CD34+ precursor cells showed that individually assayed cells, removed from companion cells that presumably provided negative signals such as TNF-alpha or Fas-ligand, were able to generate progressively increasing numbers of colonies. Stromal layers derived from MDS marrow did not have an inhibitory effect. In fact, higher colony numbers were obtained from both normal and MDS marrow derived hemopoietic precursors propagated on irradiated stromal layers from MDS marrow than on stromal layers from normal marrow. These results show that substantial numbers of normal hemopoietic precursors persist in MDS marrow. However, differentiation into mature cells is inhibited by negative signals originating from accessory or abnormal hemopoietic precursors in the non-adherent marrow fraction.


Subject(s)
Bone Marrow Cells/pathology , Hematopoiesis , Myelodysplastic Syndromes/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Cell Adhesion , Cell Separation , Cells, Cultured , Child , Child, Preschool , Cytogenetics , Female , Hematopoiesis/genetics , Humans , Immunophenotyping , Male , Middle Aged , Myelodysplastic Syndromes/classification , Myelodysplastic Syndromes/genetics , Stromal Cells/pathology
13.
Am J Clin Pathol ; 112(4): 513-23, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10510674

ABSTRACT

A vexing problem after hematopoietic cell transplantation (HCT) for leukemia is assessing the biologic significance of low numbers of cells "suspicious" for relapse seen in morphologic review of peripheral blood smears (PBSs). In 27 patients, in apparent hematologic remission after HCT for leukemia, we studied the nature of such cells in PBSs to the endpoint of leukemic relapse by using multidimensional flow cytometry (MDF) on blood or bone marrow aspirates. Based on abnormal cytometric maturational patterns, +/- cell sorting of blasts with fluorescence in situ hybridization with informative markers, we differentiated benign recovering myeloid and lymphoid precursors from leukemic cells. In 17 patients, blasts were characterized by MDF as normal early hematopoietic precursors, lymphoblasts, or NK cells. Of these patients, 16 remained in remission for at least 42 days. In 10 patients, blasts were characterized by MDF as a malignant immunophenotype; 9 relapsed within 10 days and 1 relapsed 280 days after a graft-vs-leukemia effect. MDF status was strongly associated with a 90 x probability of relapse even after adjusting for other potential variables. Morphologic triggered MDF characterization of peripheral blasts is a powerful and rapid tool for distinguishing immature regenerative forms from early leukemic relapse.


Subject(s)
Blast Crisis/etiology , Flow Cytometry , Hematopoietic Stem Cell Transplantation/adverse effects , Adolescent , Adult , Cell Separation , Child , Child, Preschool , Female , Humans , Immunophenotyping , In Situ Hybridization, Fluorescence , Leukemia/therapy , Male , Middle Aged , Prognosis
14.
Leukemia ; 12(12): 2015-23, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9844932

ABSTRACT

Patients with unexplained cytopenias often present a diagnostic dilemma with minimal morphologic or cytogenetic changes to identify the underlying disease process. We have used multidimensional flow cytometry in a study of patients with cytopenias and found that this technology established, changed, or refined the diagnosis in 17/121 patients. Using the flow cytometric technique of CD45 and right angle light scatter (SSC) gating with two additional markers in a three-color analysis, eight of 121 patients were found to have hairy cell leukemia (HCL), in the absence of definitive morphologic findings of HCL. Two additional patients were found to have non-Hodgkin's lymphoma (NHL). Myeloid abnormalities, myelodysplasia (MDS) or acute leukemia was detected in seven of 56 patients with unexplained pancytopenia. Six of 65 patients identified with cytopenias resulting from lymphoid neoplasms had been referred for bone marrow transplantation (BMT) with a presumptive diagnosis of MDS, with subsequent deferral of BMT upon correct diagnosis. The screening technique is incorporated into an extensive immunophenotyping scheme to identify hematopoietic abnormalities using multidimensional flow cytometry (MDF). HCL cells (detected as low as 1.3%) reside in the same position as normal monocytes in the CD45 and SSC plots but could be distinguished from monocytes based on the expression of HLA-DR without CD11b, and expression of CD19. Further phenotyping of the abnormal population confirmed immunoglobulin light chain restriction, CD11c, and CD25 expression. Non-Hodgkin's lymphoma was detected as aberrant mature lymphocytes expressing B lymphoid markers, CD5 and light chain restriction. Myeloid abnormalities were identified in the myeloblast or maturing myeloid cell fractions. The flow cytometric scheme described can be used in primary diagnosis. The technique is definitive, sensitive, and stresses the importance of distinguishing lymphoid from myeloid etiology of cytopenias.


Subject(s)
Flow Cytometry/methods , Leukemia, Hairy Cell/diagnosis , Leukemia, Myeloid/diagnosis , Lymphoma, Non-Hodgkin/diagnosis , Myelodysplastic Syndromes/diagnosis , Acute Disease , Adult , Aged , Aged, 80 and over , Diagnosis, Differential , Female , Humans , Leukemia, Hairy Cell/complications , Leukemia, Myeloid/complications , Lymphoma, Non-Hodgkin/complications , Male , Middle Aged , Myelodysplastic Syndromes/complications , Pancytopenia/etiology , Retrospective Studies
15.
Br J Haematol ; 103(1): 176-88, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9792306

ABSTRACT

Apoptosis of haemopoietic cells in the marrow of patients with myelodysplastic syndrome (MDS) has been suggested as a mechanism for peripheral cytopenias. We determined the expression of Fas (CD95), Fas-Ligand (Fas-L) and TNF-alpha factors known to be involved in apoptosis, in the marrow of 44 patients with MDS and characterized their functional relevance in in vitro assays of haemopoiesis. Multidimensional flow cytometry revealed phenotypically aberrant blasts as defined by orthogonal light scatter and CD45 expression in the marrow of 24/44 patients. Among those blasts Fas expression was increased on CD34-positive cells and on cells co-expressing HLA-DR. In addition, Fas-L was expressed on some CD34+ cells of MDS patients but was never detected on CD34+ cells in normal marrow. Fas and Fas-L mRNAs as well as mRNA for TNF-alpha, known to increase Fas expression in normal marrow, were up-regulated in patients with MDS. TNF-alpha protein and sTNF-R1 levels in marrow plasma were higher in MDS patients than in controls (P<0.002 and <0.003, respectively). However, results were dependent upon disease category: TNF-alpha levels were significantly higher in patients with refractory anaemia (RA) than in patients with RA with excess blasts (RAEB) or RAEB in transformation (RAEB-T) (P=0.043). Conversely, the proportion of Fas-L-positive cells was lowest in patients with RA (P=0.037). In marrow cultures, Fas-Ig, rhuTNFR:Fc or anti-TNF-alpha antibody, by blocking Fas or TNF mediated signals, respectively, significantly increased the numbers of haemopoietic colonies compared to untreated cells (P<0.001, P<0.003, P<0.001, respectively). These results show significant dysregulation in the expression of TNF-alpha, Fas and Fas-L in the marrow from MDS patients. Altered expression of these molecules appears to be of functional relevance in the dysregulation of haemopoiesis in MDS and may be amenable to therapeutic interventions.


Subject(s)
Bone Marrow Diseases/metabolism , Hematopoiesis/physiology , Membrane Glycoproteins/metabolism , Multiple Myeloma/metabolism , Tumor Necrosis Factor-alpha/metabolism , fas Receptor/metabolism , Adolescent , Adult , Aged , Apoptosis/physiology , Bone Marrow Cells/metabolism , Bone Marrow Cells/pathology , Bone Marrow Diseases/etiology , Bone Marrow Diseases/pathology , Child , Fas Ligand Protein , Female , Flow Cytometry , Humans , Lymphocytes/metabolism , Lymphocytes/pathology , Male , Middle Aged , Monocytes/metabolism , Monocytes/pathology , Multiple Myeloma/complications , Multiple Myeloma/pathology , Receptors, Tumor Necrosis Factor/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods
16.
Am J Clin Pathol ; 110(1): 84-94, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9661926

ABSTRACT

Serial bone marrow aspirates from patients previously given a diagnosis of acute lymphoblastic leukemia (ALL) who had undergone chemotherapy, bone marrow transplantation (BMT), or both were analyzed by multidimensional flow cytometry (MDF) to detect residual disease (lower limit of detection 0.3%). Correlation between the results of morphologic examination and MDF showed concordant results on 100 of 118 specimens. The MDF-positive, morphologic examination-negative specimens were positive by cytogenetic examination or were obtained from patients in whom the ALL eventually relapsed. Similar correlations between MDF and the results of cytogenetic examination were obtained. Leukemic cells were detected in 29 of 62 patients before BMT and 12 of 52 after BMT Normal regenerating lymphoblasts were identified and quantified by MDF in patients without detectable leukemic lymphoblasts. Patients with leukemic lymphoblasts found by MDF in specimens obtained immediately before BMT were 3.28 times more likely to experience relapse after BMT compared with MDF-negative patients, even when leukemic lymphoblasts were undetectable by histopathologic examination, cytogenetic examination, or both. All patients who had undergone BMT with leukemic lymphoblasts found by MDF, with or without morphologic or cytogenetic confirmation, experienced relapse according to conventional criteria within 42 days of the MDF analysis. The detection of residual disease before overt relapse may provide information for early intervention, while definitive recognition of normal recovering blasts may prevent unnecessary treatment.


Subject(s)
Antineoplastic Agents/therapeutic use , Bone Marrow Cells/pathology , Bone Marrow Transplantation , Granulocytes/pathology , Lymphocytes/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Adolescent , Adult , B-Lymphocytes/immunology , Bone Marrow Examination , Cell Separation , Child , Child, Preschool , Female , Flow Cytometry , Granulocytes/immunology , Humans , Immunophenotyping , Infant , Karyotyping , Lymphocyte Subsets , Lymphocytes/immunology , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
17.
Leuk Lymphoma ; 25(5-6): 403-14, 1997 May.
Article in English | MEDLINE | ID: mdl-9250810

ABSTRACT

Expression of T, sialosyl-T and disialosyl-T antigens on normal blood and bone marrow cells as well as transformed cells was examined using specific monoclonal antibodies and multidimensional flow cytometry. Both anti-sialosyl-T (QSH1) and anti-disialosyl-T (QSH2) monoclonal antibodies aggregated erythrocytes. The anti-disialosyl-T antibody was specific for the erythroid lineage and did not react with neutrophils, monocytes or T-lymphocytes, while the anti-sialosyl-T antibody reacted with erythroid cells and a subset of T-lymphocytes. The developing erythroid cells in bone marrow showed coordinate expression of glycophorin A and the two carbohydrate chains, sialosyl-T and disialosyl-T. Analysis of neoplastic cells showed that the anti-disialosyl-T antibody only reacted with glycophorin A-positive blasts from erythroleukemia (FAB M6) patients (4/4) and one patient with chronic myeloid leukemia in erythroblastic transformation (CMLET). Leukemic blasts from these patients demonstrated coordinate quantitative expression of glycophorin A and disialosyl-T. The anti-sialosyl-T antibody reacted with glycophorin A-positive blasts from FAB M6 patients (4/4) and one CMLET patient; however, the antibody also reacted with glycophorin A-negative blasts from one FAB M6 and the one CMLET patients and transformed cells from other types of leukemia. The anti-T monoclonal antibody (HH8) did not react with any of the other cells tested. These results indicate that glycophorin A and disialosyl-T expression are tightly linked during normal erythroid development and erythroid leukemogenesis.


Subject(s)
Antigens, Surface/metabolism , Erythrocytes/metabolism , Leukemia/metabolism , Mucins/metabolism , Oligosaccharides/metabolism , Antigens, Surface/blood , Carbohydrate Sequence , Glycophorins/metabolism , Humans , Leukemia/blood , Molecular Sequence Data , Mucins/blood , Oligosaccharides/blood
18.
J Natl Cancer Inst ; 88(20): 1483-8, 1996 Oct 16.
Article in English | MEDLINE | ID: mdl-8841024

ABSTRACT

BACKGROUND: Most patients receiving therapy for acute myeloid leukemia (AML) enter an interval in which leukemic blast cells cannot be detected by light microscopy (i.e., morphologic remission). However, many of these patients experience a subsequent relapse. Multidimensional flow cytometry, which allows the discrimination of antigens expressed on normal and malignant cells, can detect small numbers of cancer cells in bone marrow or peripheral blood specimens. This technique enables the detection of one leukemic blast cell among 10(3) to 10(2) normal regenerating hematopoietic cells. PURPOSE: We determined whether the presence of residual leukemic blast cells, identified in the bone marrow of pediatric patients with AML by use of multidimensional flow cytometry, would be predictive of subsequent leukemic relapse. METHODS: Multidimensional flow cytometry was performed on 205 marrow specimens collected throughout the course of treatment from 39 patients who had achieved morphologic remission. The analyses employed monoclonal antibodies directed against CD45 in combination with mixed pairs of monoclonal antibodies directed against 10 other antigens. A time-varying Cox regression analysis that controlled for sample time intervals, age, sex, morphologic classification of disease, and white blood cell count at diagnosis was used to relate the multidimensional flow cytometric results to the risk of relapse after achieving remission. Reported P values are two-sided. RESULTS: Thirty-five of the 39 patients had bone marrow specimens available from the time that first morphologic remission was achieved. Leukemic blast cells were detected in the specimens from 19 (54%) of these 35 patients. Twenty-five of the 35 patients did not receive an allogeneic (i.e., from a different genetic background) bone marrow transplant during first morphologic remission, and 13 of 14 with residual leukemic cells experienced a relapse at a median time of 153 days after diagnosis (range, 48-863 days). Nine of the 11 patients who did not receive an allogeneic bone marrow transplant and lacked evidence of leukemic blast cells at first morphologic remission relapsed at a median time of 413 days after diagnosis (range, 321-794 days). Among the 10 individuals who received an allogeneic bone marrow transplant during first morphologic remission, five were positive for leukemic blast cells and five were negative; one of these patients (positive for leukemic blast cells) experienced a relapse 265 days after diagnosis, and three others died of transplant-related complications. The estimated risk of relapse during intervals of multidimensional flow cytometric positivity (i.e., intervals of remission for which the immediately preceding cytometry measurement was positive) was 2.8 times greater than that during negative intervals (95% confidence interval = 1.1-7.0; P = .02). CONCLUSIONS AND IMPLICATIONS: Multidimensional flow cytometry identifies residual leukemia in more than half of the patients with AML who are in morphologic remission. The detection of leukemic blast cells in these patients by multidimensional flow cytometry is predictive of a more rapid relapse.


Subject(s)
Flow Cytometry , Leukemia, Myeloid/diagnosis , Acute Disease , Adolescent , Antibodies, Monoclonal , Antigens, Neoplasm/immunology , Child , Child, Preschool , Female , Flow Cytometry/methods , Humans , Immunophenotyping , Infant , Leukemia, Myeloid/immunology , Male , Neoplasm, Residual , Predictive Value of Tests , Prognosis , Recurrence , Risk
19.
Blood ; 88(2): 622-32, 1996 Jul 15.
Article in English | MEDLINE | ID: mdl-8695810

ABSTRACT

Aneuploidy and lg light chain restriction were used as separate, independent tumor specific markers to study 26 patients with multiple myeloma to determine whether bone marrow B cells, as defined by CD19 expression, are clonally related to myeloma plasma cells. Specimens were characterized using multidimensional flow cytometry to identify the presence of clonality in both the B lymphoid and plasma cell populations using both surface and cytoplasmic staining with antibodies specific for kappa or lambda lg light chain In none of the patients with multiple myeloma were CD19+ cells found to be clonally restricted to kappa or lambda. The monoclonal plasma cells (MPC) were found to be uniformly negative for CD10, CD19, and CD34, while the CD19+ B lymphoid cells present within the samples expressed normal intensities and relationships of these antigens, which allowed them to serve as internal positive controls. Combined analysis of call surface antigen expression and DNA content allowed plasma cell populations to be characterized for aneuploidy without interference from normal bone marrow cells. The MPC, detected on the basis of bright CD38 expression (CD38+2), demonstrated DNA aneuploidy in 65% of cases (DNA index range of 0.9 to 1.3). These aneuploid DNA distributions had typical cell cycle profiles (including G1,S and G2+M) expected of a proliferating population. In all cases, DNA aneuploidy was confined almost entirely to the CD38+2, CD19- malignant plasma cells, while cells expressing CD19 were diploid. These results support the concept that myeloma is a disease process mediated by self-replicating, late compartments of B-cell ontogeny.


Subject(s)
Aneuploidy , Antigens, CD19/analysis , Antigens, CD , Antigens, Neoplasm/analysis , B-Lymphocyte Subsets/ultrastructure , Multiple Myeloma/genetics , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Adult , Aged , Aged, 80 and over , Antigens, Differentiation/analysis , Bone Marrow/pathology , Cell Cycle , Cell Lineage , DNA, Neoplasm/analysis , Diploidy , Female , Flow Cytometry , Gene Rearrangement, B-Lymphocyte, Light Chain , Humans , Immunophenotyping , Male , Membrane Glycoproteins , Middle Aged , Multiple Myeloma/pathology , Myeloma Proteins/genetics , N-Glycosyl Hydrolases/analysis , Neoplastic Stem Cells/ultrastructure , Plasma Cells/ultrastructure
20.
J Pediatr Hematol Oncol ; 17(2): 123-33, 1995 May.
Article in English | MEDLINE | ID: mdl-7749761

ABSTRACT

Techniques to assay minimal residual disease are available for most patients with acute lymphoblastic leukemia, non-Hodgkin's lymphoma, breast cancer, Ewing's sarcoma, and others. Today, a few such tests exist for acute myelogenous leukemia (AML). This review evaluates the tests available for assessing minimal residual disease in AML: morphology, growth in vitro, cytogenetics, magnetic resonance imaging, polymerase chain reaction (PCR)-based assays for translocation products, and multiparameter flow cytometry. Of these, multiparameter flow cytometry appears most promising. Studies using multiparameter flow cytometry to identify leukemic cells by aberrant antigen expression have reported a high positive predictive value with regard to the incidence of relapse. In addition, the test is specific, rapid, inexpensive, and applicable to a sufficiently broad group of patients, allowing its use outside of the research laboratory setting. Judicious use of some of the available assays singly or in combination should identify patients harboring residual leukemic cells.


Subject(s)
Leukemia, Myeloid, Acute/diagnosis , Leukemia, Myeloid, Acute/pathology , Flow Cytometry , Forecasting , Humans , In Situ Hybridization, Fluorescence , Leukemia, Myeloid, Acute/genetics , Magnetic Resonance Imaging , Neoplasm, Residual , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...